These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 24523105)

  • 21. High performance enzyme kinetics of turnover, activation and inhibition for translational drug discovery.
    Zhang R; Wong K
    Expert Opin Drug Discov; 2017 Jan; 12(1):17-37. PubMed ID: 27784173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition.
    Yang J; Jamei M; Yeo KR; Tucker GT; Rostami-Hodjegan A
    Eur J Pharm Sci; 2007 Jul; 31(3-4):232-41. PubMed ID: 17512176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro ADME phenotyping in drug discovery: current challenges and future solutions.
    Williams JA; Bauman J; Cai H; Conlon K; Hansel S; Hurst S; Sadagopan N; Tugnait M; Zhang L; Sahi J
    Curr Opin Drug Discov Devel; 2005 Jan; 8(1):78-88. PubMed ID: 15679175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enzyme kinetics of conjugating enzymes: PAPS sulfotransferase.
    James MO
    Methods Mol Biol; 2014; 1113():187-201. PubMed ID: 24523114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of drug-drug interactions: concepts and approaches.
    Weaver RJ
    Xenobiotica; 2001; 31(8-9):499-538. PubMed ID: 11569524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apparent aberrancy in the kinetics of intracellular metabolism of a single substrate by two enzymes. An alternative explanation for anomalies in the kinetics of sulfation and glucuronidation.
    Koster H; Mulder GJ
    Drug Metab Dispos; 1982; 10(4):330-5. PubMed ID: 6126330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of clearance concepts and modeling techniques in the prediction of metabolic drug-drug interactions.
    Ito K; Sugiyama Y
    Trends Pharmacol Sci; 2010 Aug; 31(8):351-5. PubMed ID: 20542578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular basis of ethnic differences in drug disposition and response.
    Xie HG; Kim RB; Wood AJ; Stein CM
    Annu Rev Pharmacol Toxicol; 2001; 41():815-50. PubMed ID: 11264478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption.
    Harwood MD; Neuhoff S; Carlson GL; Warhurst G; Rostami-Hodjegan A
    Biopharm Drug Dispos; 2013 Jan; 34(1):2-28. PubMed ID: 22927116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug-metabolism research challenges in the new millennium: individual variability in drug therapy and drug safety.
    Lu AY
    Drug Metab Dispos; 1998 Dec; 26(12):1217-22. PubMed ID: 9860931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exact and approximate solutions for the decades-old Michaelis-Menten equation: Progress-curve analysis through integrated rate equations.
    Goličnik M
    Biochem Mol Biol Educ; 2011; 39(2):117-25. PubMed ID: 21445903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nuclear receptors in regulation of biotransformation enzymes and drug transporters in the placental barrier.
    Pavek P; Smutny T
    Drug Metab Rev; 2014 Feb; 46(1):19-32. PubMed ID: 24020384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The challenges of dealing with promiscuous drug-metabolizing enzymes, receptors and transporters.
    Ma Q; Lu AY
    Curr Drug Metab; 2008 Jun; 9(5):374-83. PubMed ID: 18537574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enzyme databases.
    Schomburg D; Schomburg I
    Methods Mol Biol; 2010; 609():113-28. PubMed ID: 20221916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions-an Industry Perspective.
    Bohnert T; Patel A; Templeton I; Chen Y; Lu C; Lai G; Leung L; Tse S; Einolf HJ; Wang YH; Sinz M; Stearns R; Walsky R; Geng W; Sudsakorn S; Moore D; He L; Wahlstrom J; Keirns J; Narayanan R; Lang D; Yang X;
    Drug Metab Dispos; 2016 Aug; 44(8):1399-423. PubMed ID: 27052879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-time monitoring of mass-transport-related enzymatic reaction kinetics in a nanochannel-array reactor.
    Li SJ; Wang C; Wu ZQ; Xu JJ; Xia XH; Chen HY
    Chemistry; 2010 Sep; 16(33):10186-94. PubMed ID: 20645335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Stationary kinetics of multisubstrate enzymatic reactions. Inhibition by reaction products, reversible and irreversible inhibitors].
    Vrzheshch PV
    Biokhimiia; 1988 Oct; 53(10):1704-11. PubMed ID: 3233227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of overloading pathways on toxicity.
    Wolf FJ
    J Environ Pathol Toxicol; 1980; 3(5-6):113-34. PubMed ID: 7441076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of hepatic uptake transporters on pharmacokinetics and drug-drug interactions: use of assays and models for decision making in the pharmaceutical industry.
    Soars MG; Webborn PJ; Riley RJ
    Mol Pharm; 2009; 6(6):1662-77. PubMed ID: 19402709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model.
    Houston JB; Kenworthy KE
    Drug Metab Dispos; 2000 Mar; 28(3):246-54. PubMed ID: 10681367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.